Sucampo Pharmaceuticals, Inc. Release: Lubiprostone Successfully Completes Phase 3 Efficacy Trial in Japanese Patients Suffering from Chronic Idiopathic Constipation
BETHESDA, Md. & ABBOTT PARK, Ill.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) and Abbott (NYSE:ABT) today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data.